Celyad Oncology S.A.
CLYYF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $15,567 | $29,497 | $6,945 | $11,251 |
| - Cash | $790 | $4,200 | $6,229 | $7,004 |
| + Debt | $831 | $17,536 | $989 | $902 |
| Enterprise Value | $15,608 | $42,833 | $1,705 | $5,149 |
| Revenue | $14 | $172 | $14 | $58 |
| % Growth | -91.9% | 1,128.6% | -75.9% | – |
| Gross Profit | -$198 | -$52 | $5 | $33 |
| % Margin | -1,414.3% | -30.2% | 35.7% | 56.9% |
| EBITDA | -$3,609 | -$2,602 | -$2,789 | -$4,468 |
| % Margin | -25,775% | -1,512.8% | -19,921.4% | -7,703.4% |
| Net Income | -$3,700 | -$2,779 | -$3,044 | -$4,708 |
| % Margin | -26,428.6% | -1,615.7% | -21,742.9% | -8,117.2% |
| EPS Diluted | -0.089 | -0.067 | -0.12 | -0.16 |
| % Growth | -33.2% | 44.1% | 25% | – |
| Operating Cash Flow | $0 | -$2,849 | -$2,831 | -$6,871 |
| Capital Expenditures | $0 | -$118 | $0 | -$583 |
| Free Cash Flow | $0 | -$2,849 | -$2,831 | -$7,454 |